Retinal Cell Biology

A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury

Alex Woodell,1 Bryan W. Jones,2 Tucker Williamson,3 Gloriane Schnabolk,4 Stephen Tomlinson,3,4 Carl Atkinson,3,5 and Bärbel Rohrer1,4,6

1Department of Neuroscience, Medical University of South Carolina, Charleston, South Carolina, United States
2Moran Eye Center, University of Utah, Salt Lake City, Utah, United States
3Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, United States
4Research Service, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States
5Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, United States
6Department of Ophthalmology, Medical University of South Carolina, Charleston, South Carolina, United States

CORRESPONDENCE: Bärbel Rohrer, Department of Ophthalmology, Medical University of South Carolina, 167 Ashley Avenue, Charleston, SC 29425, USA; rohrer@musc.edu.
Carl Atkinson, Department of Microbiology and Immunology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425, USA; atkinsoc@musc.edu.
Submitted: October 21, 2015
Accepted: January 9, 2016

PURPOSE. Morphologic and genetic evidence exists that an overactive complement system driven by the complement alternative pathway (AP) is involved in pathogenesis of age-related macular degeneration (AMD). Smoking is the only modifiable risk factor for AMD. As we have shown that smoke-related ocular pathology can be prevented in mice that lack an essential activator of AP, we ask here whether this pathology can be reversed by increasing inhibition in AP

METHODS. Mice were exposed to either cigarette smoke (CS) or filtered air (6 hours/day, 5 days/week, 6 months). Smoke-exposed animals were then treated with the AP inhibitor (CR2-fH) or vehicle control (PBS) for the following 3 months. Spatial frequency and contrast sensitivity were assessed by optokinetic response paradigms at 6 and 9 months; additional readouts included assessment of retinal morphology by electron microscopy (EM) and gene expression analysis by quantitative RT-PCR.

RESULTS. The CS mice treated with CR2-fH showed significant improvement in contrast threshold compared to PBS-treated mice, whereas spatial frequency was unaffected by CS or pharmacologic intervention. Treatment with CR2-fH in CS animals reversed thinning of the retina observed in PBS-treated mice as analyzed by spectral-domain optical coherence tomography, and reversed most morphologic changes in RPE and Bruch’s membrane seen in CS animals by EM.

CONCLUSIONS. Taken together, these findings suggest that AP inhibitors not only prevent, but have the potential to accelerate the clearance of complement-mediated ocular injury. Improving our understanding of the regulation of the AP is paramount to developing novel treatment approaches for AMD.

Keywords: alternative complement pathway, CR2-fH, knockout mouse, smoke exposure, mitochondria, Bruch’s membrane deposits, dry age-related macular degeneration

Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness among the elderly in developed countries and is projected to affect 196 million people by 2020.1 Age-related macular degeneration is a progressive, degenerative disease of the retina that results in central vision loss caused by the degeneration of photoreceptor cells. This late-onset maculopathy can be diagnosed in two forms: atrophic, “dry”; or neovascular, “wet.”2 The atrophic form of the disease is marked by the formation of lipoprotein deposits known as drusen in the subretinal space between Bruch’s membrane (BrM) and the retinal pigment epithelium (RPE). The neovascular form is characterized by the proliferation of choroidal blood vessels (choroidal neovascularization, CNV) through BrM into the subretinal space. These fragile vessels leak fluid and proteins into the subretinal or sub-RPE space,3 leading to retinal detachment followed by photoreceptor cell death. Patients can develop either form of the disease; however, the atrophic form is most common, making up 90% of all cases.4

Age-related macular degeneration is a multiplex disease that is influenced by genetic and environmental factors. Many of the main genetic risk factors are polymorphisms occurring in complement genes, a system whose role spans clearance of pathogens to mediating the induction and expansion of inflammatory injury. These genes include the complement alternative pathway (AP) inhibitor FH (factor H), the AP activator FB (factor B), and complement components C2 and C3. The most well known of these is the Y402H in FH. Its risk variant has been associated with increased levels of granulocyte macrophage colony-stimulating factor in the vitreous and an accumulation of choroidal macrophages, suggesting that a dysregulation of the proinflammatory cytokines locally in the eye underlies disease
CR2-fH reverses smoke-induced ocular injury

Increased levels of inflammation may be caused by poor binding of the 402H variants of factor H-like protein and FH to BrM due to an impaired ability to bind heparan sulphate. Furthermore, ranibizumab, a common antiangiogenic used to treat AMD, has been shown to be either more or less effective depending on expression of the Y402H allele.

Cigarette smoke is the most significant environmental factor contributing to AMD. Smoking promotes the progression of AMD from the atrophic to the neovascular form, and cessation has been shown to decrease the risk of developing AMD and the progression to CNV. The exact mechanism(s) responsible for a smoker's susceptibility to AMD is unknown, due in part to the large number of constituents in cigarette smoke and the potential for other contributing factors. Both cigarette smoke and hydroquinone, a component of cigarette smoke, induce oxidative damage and apoptosis in human RPE cells.

Hydroquinone also downregulates proinflammatory monocyte chemoattractant protein-1 and upregulates vascular endothelial growth factor (VEGF) in RPE cells, suggesting that incomplete clearance of proinflammatory debris could be responsible for a smoker's susceptibility to AMD. Increased levels of inflammation may promote drusen formation and progression to CNV in AMD patients. Finally, smoke extract has been shown to directly activate C3 and trigger complement-dependent endoplasmic reticulum stress and lipid deposition in ARPE-19 cells, providing a clear link between smoking and complement activation.

Previous studies by the Neufeld group have shown that mice with long-term cigarette smoke exposure (CSE) exhibit activation of the terminal pathway of the complement system in the RPE and choroid, concomitant with damage to the RPE and photoreceptors. We followed up on these findings by investigating the effects of long-term CSE in wild-type (WT) mice or mice lacking a functional AP (FB KO). Cigarette smoke exposure in WT mice resulted in functional (decreases in rod and cone electroretinography amplitudes), behavioral (decrease in cone-dependent contrast sensitivity), morphologic (increase in mitochondrial size in the RPE, thickening of BrM) impairment, while FB KO mice were protected from developing any CSE-mediated alterations. In addition, we showed that C3d deposition could be identified in the RPE, BrM, and choriocapillaris, which was correlated with alterations in gene expression of complement components in the RPE-choroid fraction of the eye (increase in activators and a decrease in complement inhibitors). Using a novel model of smoking cessation, we expanded on these findings by investigating whether the detrimental effects caused by CSE are reversible following smoking cessation and treatment with the tissue-targeted AP inhibitor, CR2-fH. CR2-fH consists of the N-terminus of mouse complement factor H (short consensus repeats [SCR] 1–5), which contains the AP-inhibitory domain, linked to a complement receptor 2 (CR2) targeting fragment that binds complement activation products. The CR2 domain allows for targeting of the inhibitor factor H (FH) to sites of complement activation, and makes the CR2-fH protein independent of the endogenous ligand-binding domains present in CFH (SCR 6–8 and SCR 19/20) as shown in vitro and in vivo studies.

Materials and Methods

Animals

C57BL/6j mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and housed under a 12:12-hour light:dark cycle with access to food and water ad libitum. For intraperitoneal injections, a 25-gauge needle was inserted, and a 100-μL volume was injected (250 μg CR2-fH in PBS or PBS only). CR2-fH-expressing CHO cells were generously provided by S Tomlinson, and protein was generated and purified as published previously. Dosing and treatment schedules are outlined in the Results section. All experiments were approved by the Medical University of South Carolina Institutional Animal Care and Use Committee and performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Exposure to Cigarette Smoke

Eight-week-old C57BL/6j male mice were divided into three groups (n = 6 per group). The control group was kept in a filtered air environment, and the two experimental groups were subjected to cigarette smoke. Cigarette smoke exposure was carried out (5 hours per day, 5 days per week) by burning 3R4F reference cigarettes (University of Kentucky, Louisville, KY, USA) using a smoking machine (model TE-10; Teague Enterprises, Woodland, CA, USA) for 6 months as published previously. Cigarette smoke exposure as determined in venous blood by dual beam spectrophotometry were between 8% and 12% immediately after exposure, which is consistent with values reported in the literature for modeling the effects of chronic CSE. The average concentration of total suspended particulates present in the chamber was 150 mg/m³ and was monitored twice daily. Following 6 months of CSE, smoke-exposed animals were randomized into two groups (1, control PBS; 2, CR2-fH treated), and mice were followed for 12 weeks post smoking cessation. During this cessation period mice were exposed to normal room air.

Optokinetic Response Test

Visual acuity and contrast sensitivity of mice were measured by observing their optomotor responses to moving sine-wave gratings (OptoMotry; Cerebral Mechanics, Inc., Lethbridge, AB, Canada) as previously described. Mice reflexively respond to rotating vertical gratings by moving their head in the direction of grating rotation. To observe these movements, mice were placed individually on the central elevated pedestal surrounded by a square array of computer monitors that display stimulus gratings. Mice were monitored via an overhead closed-circuit TV camera that allowed the observer to view only the central platform and not the rotating grating. Mice were allowed to adjust to the chamber for 2 minutes with the monitors displaying a 50% gray uniform field prior to testing, and monitors returned to a homogenous gray between trials. All tests were conducted under photopic conditions with a mean luminance of 52 cd m⁻². Visual acuity was measured by finding the spatial frequency threshold of each animal at a constant speed (12°/s) and contrast (100%) with a staircase procedure that systematically increased the spatial frequency of the grating until the animal no longer exhibited detectable responses. Contrast sensitivity was determined by taking the reciprocal of the contrast threshold at a fixed spatial frequency (0.131 cycle/deg) and speed (12°/s). It has previously been determined that this spatial frequency falls within the range of maximal contrast sensitivity for 9-month-old C57BL/6j mice (data not shown). Contrast of the pattern was decreased systematically in a staircase manner until the animal stopped responding.

Tissue Preparation

The eyes were enucleated, and a slit was cut into the cornea to allow for rapid influx of fixative. Eyes were fixed overnight in 2.5% glutaraldehyde, 1% formaldehyde, 3% sucrose, and 1 mM MgSO₄ in 0.1 M cacodylate buffer, pH 7.4. The eyes were then dissected, and small central portions were osmicated for 60
minutes in 0.5% OsO4 in 0.1 M cacodylate buffer, processed in maleate buffer for en bloc staining with uranyl acetate, dehydrated in graded ethanol, and processed for resin embedding as published previously.35 Serial sections were cut at 90 nm on a Leica Ultramicrotome (Buffalo Grove, IL, USA) onto carbon-coated Formvar films supported by nickel slot-grids.

**Ultrastructural Analysis**

Electron microscopy images were captured using a JEOL JEM 1400 (Peabody, MA, USA) transmission electron microscope using SerialEM (Peabody, MA, USA) software to automate image capture overnight with 1200 to 1500 images captured per section, yielding datasets that were then processed with the NCR Toolset36,37 to generate image mosaics with corrections for image aberrations induced by electron microscopy.

Images were evaluated using Adobe Photoshop (Adobe Systems, San Jose, CA, USA) and ImageJ (http://imagej.nih.gov/ij/; provided in the public domain by the National Institutes of Health, Bethesda, MD, USA) software as published previously.21 For each animal, two RPE cells were outlined using the apical processes and the basal lamina (thickness) as well as the basolateral walls (length) as borders, and features were examined. Results from the two cells were averaged to provide a per mouse number. A masking layer for all mitochondria present within an RPE cell was created to calculate average mitochondrial number and size. To determine mitochondrial position, the centroid coordinates for each mitochondrion were calculated as a percentage of the corresponding RPE length and thickness, respectively. Coordinates were assigned to basolateral, basal, central, or apical compartments based on normalized $x$-$y$ coordinates. The BrM thickness was determined by analyzing ∼200-μm sections of BrM. A masking layer was created over segments of BrM, using choroidal intercapillary pillars and the basement membrane of the RPE and choriocapillaris (CC) as boundaries. The area of the masking layer was divided by the length of each segment to determine an average BrM thickness for each segment. We then calculated a weighted thickness average, based on the percentage length of each segment versus the entire ∼200-μm section being analyzed. Finally, we determined the average BrM thickness by summing weighted averages for each section. The number of outer collagenous layer (OCL) deposits was calculated along a ∼200-μm section of BrM. An OCL deposit was defined as the presence of any discrete focal nodule of homogenous material of intermediate electron density between the OCL of BrM and the basement membrane of the CC. Outer nuclear layer (ONL) thickness was determined by averaging measurements taken at five arbitrary points along a ∼200-μm section of retinal tissue, using the outer plexiform layer (upper) and outer limiting membrane (lower) as boundaries. Fenestrations were counted along a 100-μm section of BrM/CC and quantified as the number of fenestrations per mm. Fenestrations were identified as clearly defined gaps within the basement membrane of the CC.

**Quantitative RT-PCR**

From the second eye of each animal, RPE/choroid/sclera (henceforth referred to as RPE/choroid) and retina fractions were isolated and stored at −80°C until they were used. Quantitative RT-PCR (QRT-PCR) analyses were performed as previously described in detail.21 In short, real-time PCR analyses were performed in triplicate in a GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using standard cycling conditions. Quantitative values were obtained by the cycle number; normalizing genes of interest to β-actin, and determining fold difference between room air and CSE within treatments. See Table 1 for the full list of primers used.

**Statistics**

For data consisting of multiple groups and repeated measures, linear regression analyses of the individual animals followed by Tukey’s multiple comparisons test ($P < 0.05$) were used; single comparisons were analyzed using Student’s $t$-test assuming equal variance ($P < 0.05$; Statview; SAS Institute, Inc., Cary, NC, USA). Fold changes in QRT-PCR experiments were analyzed by $Z$-test (treatment versus never smokers; $P < 0.05$) and $t$-test using the Holm-Sidak method (CSE mice, PBS versus CR2-fH, with $α = 5.0%$; $P < 0.01$).

**Results**

**Effect of CR2-fH Treatment on Smoke-Induced Impairment of Visual Function**

There is ample evidence that morphologic and cellular alterations in dry AMD lead to vision loss or impairment as measured by changes in visual acuity and contrast sensitivity. In particular, structural changes to BrM, including thickening and lipid deposition, can lead to impaired exchange of waste and nutrients between the RPE and choroid as well as a reduction in the generation and delivery of 11-cis-retinal, the chromophore essential for proper visual function, to photoreceptor outer segments.39 However, it is unclear to what degree these changes are reversible.

Here, we generated AMD-associated morphologic alterations and loss of contrast sensitivity in mice exposed to long-term smoke inhalation as reported previously. After 6 months of CSE, animals were randomly split into two groups and assessed for visual function using optokinetic responses (reported as pretreatment data in Fig. 1). As reported previously, spatial acuity in C57BL/6J mice was not affected by CSE, resulting in acuity measures that did not differ from those of age-matched room air controls (never smokers; Fig. 1A; $P = 0.98$). However, contrast sensitivity was significantly reduced in CSE mice, which exhibited a significant decrease in contrast sensitivity compared to never smokers (group 1, to be treated with PBS; 4.57 ± 0.97; or group 2, to be treated with CR2-fH; 5.78 ± 0.52; versus never smokers: 10.14 ± 0.41; $P < 0.01$; Fig. 1B, pretreatment).

After confirming that CSE animals exhibited loss of contrast sensitivity, mice were returned to room air and treated for 3 consecutive months with either CR2-fH given three times per week or PBS, using intraperitoneal injections. CR2-fH has both a targeting domain (SCRs 1–4 of CR2) that binds C3 fragments deposited at sites of complement activation and a complement inhibitory domain (SCRs 1–5).40 After 3 months of smoking cessation and treatment, animals were retested for visual function (reported as posttreatment data in Fig. 1). As expected, spatial acuity in CSE mice treated with either PBS or CR2-fH did not differ from mice exposed to room air (Fig. 1A; $P = 0.44$). On the other hand, CSE mice treated with PBS still exhibited a robust decrease in contrast sensitivity (smoke + PBS; 4.89 ± 1.14)
Compared to never smokers (control; 9.97 ± 0.53; P < 0.001; Fig. 1B, posttreatment). Importantly, contrast sensitivity threshold in CSE mice treated with CR2-fH recovered to levels similar to those of age-matched never smokers (smoke threshold in CSE mice treated with CR2-fH recovered to 0.39; P = 0.53 versus control never smokers: 9.14 ± 0.53; P < 0.001; Fig. 1B, posttreatment). Importantly, contrast sensitivity threshold in CSE mice treated with CR2-fH recovered to levels similar to those of age-matched never smokers (smoke threshold in CSE mice treated with CR2-fH recovered to 0.39; P = 0.53 versus control never smokers: 9.14 ± 0.53; P < 0.001; Fig. 1B, posttreatment).

**Table 1. Quantitative RT-PCR Primer Sequences**

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Symbol</th>
<th>Forward and Reverse Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhodopsin</td>
<td>Rbo</td>
<td>5'-CTTCCCACTCAAACTTCCCTCA-3'</td>
</tr>
<tr>
<td>Opsin1 (cone pigments), short-wave-sensitive</td>
<td>Opn1mw</td>
<td>5'-TTGGCTTTGGTAACGGTGTCC-3'</td>
</tr>
<tr>
<td>Opsin1 (cone pigments), medium-wave-sensitive</td>
<td>Opn1mw</td>
<td>5'-TGGCTTTGGTAACGGTGTCC-3'</td>
</tr>
<tr>
<td>Retinal pigment epithelium-specific protein</td>
<td>Rpe-65</td>
<td>5'-CTTCCCACTTGGAAAGTCACCAG-3'</td>
</tr>
<tr>
<td>Complement component 3</td>
<td>C3</td>
<td>5'-TGAAACAGGGGAAAGCTCCT-3'</td>
</tr>
<tr>
<td>Hemolytic complement (component complement 5)</td>
<td>Hc</td>
<td>5'-TAAACCAAGGGGTTTGGACG-3'</td>
</tr>
<tr>
<td>Complement component 9</td>
<td>C9</td>
<td>5'-CACCCTGCTCTTGCACACTGGA-3'</td>
</tr>
<tr>
<td>Complement factor B</td>
<td>Cfb</td>
<td>5'-CTTGGTCTTGGCCCTCTACTG-3'</td>
</tr>
<tr>
<td>Complement factor D (adipsin)</td>
<td>Cfd</td>
<td>5'-CAGATTTAGCTTGGGAGAC-3'</td>
</tr>
<tr>
<td>Complement factor H</td>
<td>Cfb</td>
<td>5'-TTGGCTTTGGTAACGGTGTCC-3'</td>
</tr>
<tr>
<td>Complement factor properdin</td>
<td>Cfb</td>
<td>5'-TGAAACAGGGGAAAGCTCCT-3'</td>
</tr>
<tr>
<td>CD55 (decay accelerating factor for complement)</td>
<td>Cd55</td>
<td>5'-TAAACCAAGGGGAAAGCTCCT-3'</td>
</tr>
<tr>
<td>CD59a antigen (complement regulatory protein)</td>
<td>Cd59a</td>
<td>5'-TTCCTGCTCTTGGTACCTTGTG-3'</td>
</tr>
<tr>
<td>Vascular endothelial growth factor A</td>
<td>Vegfa</td>
<td>5'-CTTGGTCTCTTGGTACCTTGTG-3'</td>
</tr>
<tr>
<td>Serine (or cysteine) peptidase inhibitor, clade F member 1</td>
<td>Serpinf1</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>Hypoxia inducible factor 1, alpha subunit</td>
<td>Hif1a</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>Ceruloplasmin</td>
<td>Cpx</td>
<td>5'-ATAAATCAACTCATGTGCGA-3'</td>
</tr>
<tr>
<td>Lysozyme 1</td>
<td>Lys1</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>Lysosomal-associated membrane protein 2</td>
<td>Lamp2</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>Microtubule-associated protein 1 light chain 3</td>
<td>Maplc3a</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>Mitofusin 1</td>
<td>Mfn1</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>Mitochondrially encoded cytochrome c oxidase 1</td>
<td>Mt-Co1</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>Dynamin 1-like</td>
<td>Dnm1l</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8</td>
<td>Nduf8</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase</td>
<td>Pfkgb2</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>Heme oxygenase (decycling) 1</td>
<td>Hmox1</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
<tr>
<td>Actin, beta</td>
<td>Actb</td>
<td>5'-CCTGACAGATTCTCTTCCCTTC-3'</td>
</tr>
</tbody>
</table>

**Effect of CR2-fH Treatment on Smoke-Induced Changes in Gene Expression**

Changes in gene expression following smoke exposure for six gene categories have been shown previously. To recap, after 6 months of CSE, expression of genes whose products are involved in photoreceptor cell function, complement inhibition, and inhibition of angiogenic and lysosomal function was
The effects of CR2-fH treatment compared to PBS treatment following smoking cessation involved two major categories: energy metabolism and complement activation. Treatment with CR2-fH prevented the massive increase in expression of FB and FD. CR2-fH was also found to reduce mitochondrial stress, as genes affecting mitochondrial fission and fusion were normalized and an increase in the protective response gene heme oxygenase 1 was observed.

Effects of CR2-fH on Morphologic Alterations in RPE-BrM Caused by Constant Smoke Exposure

Loss in contrast sensitivity following smoke exposure has previously been shown to be associated with specific morphologic alterations in RPE, BrM, and Müller cells. Here, we asked whether these same features play a role in the recovery of visual function in CSE mice treated with CR2-fH. We analyzed electron micrographs obtained from CR2-fH and PBS cohorts and age-matched never smokers, analyzing outer retina structure (Fig. 5) and the RPE/BrM/choroid interface (Fig. 4).

Bruch’s membrane is a pentalaminar structure consisting of the basement membrane of the RPE, the inner collagenous layer, the middle elastic layer, the OCL, and the basement membrane of the CC. Bruch’s membrane is thicker in CSE mice compared to never smokers. The pentalaminar structure of BrM was disrupted as evidenced by an inconsistent middle elastic layer (Figs. 4B, 4H). Areas of BrM disorganization were especially prevalent near large deposits located in the OCL (asterisks) that are absent in never smokers. These deposits were associated with lower or absent CC fenestration density (arrowheads). In contrast, never smokers exhibit a high fenestration count with few to no OCL deposits. Mitochondria (Figs. 4D–F) were significantly altered in CSE animals, characterized by poorly defined outer membranes and disorganized cristae. Never smokers displayed healthy mitochondria with clearly defined outer membranes and organized cristae. Finally, mitochondria, which in a healthy RPE cell are distributed in a basal to apical gradient but lose this arrangement in unhealthy cells such as those exposed to CSE, were found to localize in a pattern that was not different between never smokers and CSE mice in any of the four localization bins analyzed (Fig. 5). Taken together, these results are consistent with previous findings from our lab obtained from animals examined immediately following the completion of the 6-month CSE period, with the exception of the lack of mitochondrial mislocalization. Treatment with CR2-fH following CSE reversed all smoke-induced ultrastructural deficits. Bruch’s membrane appeared intact, exhibiting the full pentalaminar structure, without any apparent thickening. Few deposits were found in BrM, and fenestrations were evenly distributed along the CC. Likewise, the mitochondrial phenotype also appeared to be healthy, as evidenced by a clear outer membrane and organized cristae.

Electron microscopy results were quantified (Table 2 based on data such as those in Figs. 3, 4) focusing on morphologic correlates of energy metabolism in the RPE (mitochondria), nutrient and waste transport (BrM thickness, OCL deposit count, and fenestrations in the CC), and photoreceptor function (ONL thickness, photoreceptor cell counts, and size of Müller cells). Mitochondria were found to be significantly larger in CSE mice compared to never smokers (P < 0.05) and made up a larger percentage of total RPE cell area (P < 0.05). Mitochondrial morphology completely recovered during the 3-month CR2-fH treatment period. The total number of mitochondria was unchanged between all three groups as...
was their localization. A thickening of BrM in CSE mice was observed compared to never smokers; however, this did not reach statistical significance. Bruch’s membrane was of normal thickness in animals treated with CR2-fH. Cigarette smoke exposure triggers the formation of OCL deposits in BrM, which are maintained in CSE mice treated with vehicle ($P < 0.01$) but removed in those treated with CR2-fH. Fenestrations counted along 100-μm BrM/CC sections revealed, on average, a ∼53% decline of the fenestrations in CSE mice ($P = 0.002$), a deficit that was reduced to ∼17% in mice treated with CR2-fH, which is not statistically different from never smokers ($P < 0.01$).

In addition, we measured the thickness of the ONL, photoreceptor cell counts, and the area of the ONL occupied by Müller cells. Smoke-exposed WT mice had a significantly thinner ONL when compared to room air controls ($P < 0.05$), which is due to Müller cell hypotrophy ($P < 0.01$) as opposed to a loss in photoreceptors. In contrast, treatment with CR2-fH restored the thickness of the ONL to normal levels ($P < 0.05$) even though there was still evidence of Müller cell hypotrophy ($P < 0.01$).

**DISCUSSION**

While we confirmed and extended our previous data on retinal structure and function in mice following long-term smoke exposure, we additionally addressed two specific questions: First, are CSE-induced changes reversible upon smoke cessa-
tion; and second, since the pathologic changes are complement dependent, can we accelerate their resolution with complement inhibitory therapy?

First, are the structural and functional changes induced by CSE reversible upon cessation of smoking (smoke + PBS)? Previously, we showed that while spatial acuity is retained in mice after 6 months of CSE, contrast sensitivity is reduced by ~60%. Allowing mice to recover in room air for 3 months only marginally affected contrast sensitivity, as the threshold was still suppressed by ~50%. Similarly, the thinning of the ONL observed after 6 months of CSE is retained after 3 months of recovery, as are Muller cell atrophy, the presence of large numbers of OCL deposits in BrM, and choriocapillaris basement membrane, and the choriocapillaris endothelium has fenestrations (arrowheads) along the entire membrane. In an animal raised in room air (control, never smoker), BrM exhibits an organized pentalaminar structure consisting of RPE basement membrane, inner collagenous layer, middle elastic layer, outer collagenous layer, and choriocapillaris basement membrane, and the choriocapillaris endothelium has fenestrations along the entire membrane. (A–C) The RPE/BrM/CC in a mouse following CSE (smoke + PBS) exhibits pathologic changes. Bruch’s membrane is disorganized, no longer showing a pentalaminar structure, and large deposits (asterisks) are present in the outer collagen layer (OCL). Notably, there is significant fenestration loss and/or endothelial cell thickening adjacent to OCL deposits. (C, I) The RPE/BrM/CC appears normal in mice treated with CR2-fH following CSE (smoke + CR2-fH). The morphologic features of mitochondria shown in mice exposed to smoke mitochondria have degraded outer membranes and disorganized cristae, but normal appearance in never smokers (D) and mice treated with CR2-fH following CSE (F).

Second, is continued complement activation required to maintain the structural and functional deficits observed in CSE mice, or can damage be reversed with complement inhibition? Our group previously described a recombinant site-targeted inhibitor of the complement AP, CR2-fH. This fusion protein consists of the AP-inhibitory domain of mouse FH linked to a CR2 targeting fragment that binds membrane-bound complement activation products, and CR2-fH has been shown to reduce complement activation, reversible has not yet been addressed. However, Neuner and colleagues have posed a related question in the Muenster Aging and Retina Study. The group followed aged smokers and nonsmokers without AMD over a median of 30.9 months and reported their adjusted risk ratios for incident AMD. Of the 9.6% of subjects who progressed to AMD, the adjusted risk ratio in current smokers versus never smokers was 3.25 (95% confidence interval [1.50–7.06]), but was still significantly elevated by 1.28 (0.70–2.33) in former smokers versus never smokers.

Second, is continued complement activation required to maintain the structural and functional deficits observed in CSE mice, or can damage be reversed with complement inhibition?
intracellular metabolism, and to injury to the colon in a model of chronic colitis, to block the progression of both acute and chronic autoimmune demyelinating disease in an experimental encephalomyelitis study, and to attenuate deficits associated with cerebral and cardiac ischemia-reperfusion injury. CR2-FH has also been used to inhibit CNV, a process requiring AP activation, as well as smoke-induced lipid deposition in cultured RPE cells. However, no studies have been conducted to investigate the efficacy of this AP inhibitory protein in a dry AMD model, particularly using a therapeutic rather than preventative paradigm. Here, we show the first conclusive evidence that CR2-FH is effective in reducing and reversing smoke-induced ocular pathology in a novel smoking cessation model. We previously showed that preventing AP activation (FB KO mice) prevented the development of all CSE-mediated structural and functional alterations. Here, we asked whether CR2-FH can accelerate the reversal of pathology when applied for a 12-week period post smoking cessation. Remarkably, we found that smoke-induced decreases in contrast sensitivity can be completely reversed following treatment with CR2-FH. Functional improvement was found to correlate with an attenuation of morphologic differences in RPE/BrM/CC. Not only did CR2-FH reverse the trend toward a thicker BrM and increases in OCL deposit formation caused by CSE, but it also reversed alterations in the CC, including restoration of fenestrations in areas of close proximity to OCL deposits. In addition, CR2-FH was effective in reversing all mitochondrial impairments observed under smoke conditions. Our data suggest that inhibition of the complement AP is paramount to reversing ocular smoke pathology, and CR2-FH is a potent inhibitor of this pathway. Further experiments need to be conducted to determine the therapeutic window, most effective dosage, and ideal delivery modality for this AP inhibitor following CSE or other complement-dependent AMD models. It will be of great interest to determine how these data relate to the ocular changes found in GA patients, in particular in light of the recent findings of the phase II clinical trial for lampalizumab, in which an anti-FD monoclonal antibody applied intravitreally appeared to reduce geographic atrophy (GA) lesion size in a subpopulation of patients.

How might smoke-induced ocular pathology be reversible with complement inhibition? Affected structures such as drusen, BrM, RPE, and CC exhibit signs of complement activation and contain neoepitopes that continue to trigger complement activation. Hence, in the absence of sufficient complement inhibition, de novo complement activation triggered by the continued presence of neoantigens and complement amplification through the complement AP will continue to drive complement activation and maintain the damaged structures even in the absence of the toxic stimulus, which in the present case is smoking. This hypothesis is supported by our gene expression study, indicating a rebound effect of AP inhibition, since both of the required activators of the AP are significantly upregulated upon cessation of smoking but return to normal levels in the presence of CR2-FH. It is plausible that in the absence of continued complement activation, complement-mediated damage leading to the growth of the lesions is reduced, and reparative mechanisms including removal of debris by macrophages, and repair of cellular metabolism by mitochondrial biogenesis, can occur. However, the exact mechanism whereby CR2-FH slows down

**Figure 5.** Mitochondrial localization is normal 3 months after cessation of smoke exposure. Mitochondrial position was determined from electron micrographs (depicted in Fig. 3) by determining their centroid coordinates as a percentage of the corresponding retinal pigment epithelium (RPE) length and thickness, respectively. Each centroid was subsequently assigned to one of four bins (basolateral, basal, central, or apical) and expressed as percent of total mitochondria (MITO). Mitochondria are localized predominantly to the basolateral and basal compartments of the RPE cells with fewer localized in the central and apical portions in never smokers. While we previously reported that cigarette smoke exposure (CSE) affects the mitochondrial distribution in C57BL/6J mice after 6 months, with mitochondria exhibiting an apical shift from the basal to central compartment, mitochondrial distribution is back to normal 3 months after the cessation of CSE (smoke + PBS), and is not further affected by complement inhibition (smoke + CR2-FH).

### Table 2. Quantification of Morphologic Structures From Mice Treated With Alternative Complement Pathway Inhibitor CR2-FH Following Cigarette Smoke Exposure (CSE)

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Control</th>
<th>Smoke + PBS</th>
<th>Smoke + CR2-FH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitochondria number</td>
<td>26.92 ± 1.23</td>
<td>30.00 ± 1.53</td>
<td>30.25 ± 1.64</td>
</tr>
<tr>
<td>Mitochondria area</td>
<td>42.68 ± 2.27</td>
<td>54.62 ± 2.48*</td>
<td>45.01 ± 1.21</td>
</tr>
<tr>
<td>Mitochondria % area</td>
<td>4.71 ± 0.70</td>
<td>8.30 ± 0.65*</td>
<td>6.29 ± 0.22</td>
</tr>
<tr>
<td>BrM thickness</td>
<td>0.62 ± 0.03</td>
<td>0.80 ± 0.13</td>
<td>0.61 ± 0.05</td>
</tr>
<tr>
<td>OCL deposit count</td>
<td>7.84 ± 2.26</td>
<td>38.87 ± 7.05†</td>
<td>4.08 ± 1.42</td>
</tr>
<tr>
<td>Fenestrations</td>
<td>2234 ± 158</td>
<td>1070 ± 47†</td>
<td>1880 ± 83</td>
</tr>
<tr>
<td>ONL thickness</td>
<td>44.77 ± 1.31</td>
<td>36.86 ± 2.79*</td>
<td>44.65 ± 0.87</td>
</tr>
<tr>
<td>Photoreceptor cell count</td>
<td>38.60 ± 0.93</td>
<td>39.00 ± 1.16</td>
<td>38.00 ± 0.95</td>
</tr>
<tr>
<td>Müller cell % area</td>
<td>28.87 ± 1.37</td>
<td>18.35 ± 1.41†</td>
<td>21.90 ± 1.67†</td>
</tr>
</tbody>
</table>

All area and thickness measurements are expressed in μm² and μm, respectively. Mitochondria (MITO) measurements refer to the number area, and percentage of mitochondrial area occupied per RPE cell. Outer collagenous (OCL) deposit count reflects the number of deposits per mm. Fenestrations quantified as the numbers per mm Bruch’s membrane/choriocapillaris (BrM) length. Müller cell % area refers to the percentage of a 600-μm² area of the outer nuclear layer (ONL) occupied by Müller cells. The same area was used to count photoreceptor nuclei. Data are expressed as mean ± SEM (n = 3–6 per group).

* P < 0.05.
† P < 0.01.
or reverses the progression of disease requires further investigation.

In summary, there is a growing body of evidence linking oxidative stress, cigarette smoking, and complement activation to the development and progression of AMD. Our data provided herein demonstrate that CSE in mice causes behavioral and morphologic defects in the retina, RPE, BrM, and CC, similar to those observed in patients with dry AMD, and it persists post smoking cessation. CR2-fH administered to mice following CSE provides the first evidence that complement-based therapy is effective in treating smoke-induced ocular pathology, and suggests that this line of therapy may be effective in treating dry AMD in humans.

Acknowledgments

We thank Luanna Bartholomew, PhD, for critical review.

Supported in part by National Institutes of Health (NIH) Grants R01EY019320, R01 NHLBI 091944, NIH EY015128, NIH EY02576, and EY014800; Department of Veterans Affairs I01 RX000444, an unrestricted grant to the Medical University of South Carolina from Research to Prevent Blindness (RPB), Inc., New York, New York, United States; Vision Core, an unrestricted grant from Research to Prevent Blindness to the Moran Eye Center; Edward N. and Della L. Thome Memorial Foundation grant for Age-Related Macular Degeneration Research. Animal studies were conducted in a facility constructed with support from the NIH (C06 RR015455). CA, ST, and BR are patent holders for the use of CR2-fH in complement-dependent diseases. This patent is licensed to Alexion Therapeutics.

Disclosure: A. Woodell, None; B.W. Jones, None; T. Williamson, None; G. Schnabolk, None; S. Tomlinson, P; C. Atkinson, P; B. Rohrer, P

References


